



November 7, 2024

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-6374-9702

Notice Regarding difference between financial forecast and actual results

KYORIN Pharmaceutical Co., Ltd. announced that the following differences between the consolidated financial forecast for the interim period of fiscal year ending March 31, 2025, which were announced on May 10, 2024, and the actual consolidated financial results announced today.

1. Difference between consolidated financial results forecast and actual results for the interim period of the fiscal year ending March31, 2025

	Net Sales	Operating Profit	Ordinary Profit	Net profit attributable to shareholders of the parent company	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	56,900	1,000	1,300	900	15.67
Actual (B)	55,139	1,549	2,050	1,255	21.86
Change (B-A)	-1,761	549	750	355	—
Percentage change (%)	-3.1	+54.9	+57.7	+39.5	—

2. Reasons for the differences

Net Sales for the current accounting period were slightly below the previously announced forecast due to lower than expected sales of long-listed products and generic drugs, despite steady performance from our mainstay products. On the other hand, operating profit, ordinary profit and net profit attributable to shareholders of the parent company exceeded the previously announced forecast due to temporary differences, such as unspent R&D expenses and general costs within SG&A expenses.

The forecast for consolidated results for the full year of fiscal 2024 has not been changed from the previous forecast announced in May 10, 2024.